Announcement • Jun 02
M1 Kliniken AG, Annual General Meeting, Jul 08, 2026 M1 Kliniken AG, Annual General Meeting, Jul 08, 2026, at 11:00 W. Europe Standard Time. Reported Earnings • May 21
Full year 2025 earnings released: EPS: €1.19 (vs €0.85 in FY 2024) Full year 2025 results: EPS: €1.19 (up from €0.85 in FY 2024). Revenue: €365.5m (up 7.7% from FY 2024). Net income: €22.1m (up 38% from FY 2024). Profit margin: 6.1% (up from 4.7% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth. Declared Dividend • May 14
Dividend increased to €1.20 Dividend of €1.20 is 140% higher than last year. Ex-date: 9th July 2026 Payment date: 13th July 2026 Dividend yield will be 6.5%, which is higher than the industry average of 3.3%. Sustainability & Growth The dividend has increased by an average of 5.2% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 23% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • May 14
M1 Kliniken AG to Report Fiscal Year 2025 Final Results on May 20, 2026 M1 Kliniken AG announced that they will report fiscal year 2025 final results on May 20, 2026 Announcement • May 13
M1 Kliniken AG announces Annual dividend, payable on July 13, 2026 M1 Kliniken AG announced Annual dividend of EUR 1.2000 per share payable on July 13, 2026, ex-date on July 09, 2026 and record date on July 10, 2026. New Risk • Mar 27
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Price Target Changed • Jan 12
Price target increased by 8.4% to €28.00 Up from €25.83, the current price target is provided by 1 analyst. New target price is 49% above last closing price of €18.80. Stock is up 25% over the past year. The company is forecast to post earnings per share of €0.94 for next year compared to €0.85 last year. Upcoming Dividend • Jul 10
Upcoming dividend of €0.50 per share Eligible shareholders must have bought the stock before 17 July 2025. Payment date: 21 July 2025. Payout ratio is a comfortable 59% and this is well supported by cash flows. Trailing yield: 3.5%. Lower than top quartile of German dividend payers (4.3%). Higher than average of industry peers (2.6%). Reported Earnings • Jun 06
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: EPS: €0.85 (up from €0.54 in FY 2023). Revenue: €340.4m (up 7.6% from FY 2023). Net income: €16.0m (up 56% from FY 2023). Profit margin: 4.7% (up from 3.2% in FY 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 1.6%. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 37% per year and the company’s share price has also increased by 37% per year. Announcement • Jun 06
M1 Kliniken AG, Annual General Meeting, Jul 16, 2025 M1 Kliniken AG, Annual General Meeting, Jul 16, 2025, at 11:00 W. Europe Standard Time. Declared Dividend • May 23
Dividend of €0.50 announced Dividend of €0.50 is the same as last year. Ex-date: 17th July 2025 Payment date: 21st July 2025 Dividend yield will be 3.3%, which is about the same as the industry average. Sustainability & Growth The dividend has increased by an average of 5.8% per year over the past 9 years. However, payments have been volatile during that time. EPS is expected to grow by 44% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • May 22
M1 Kliniken AG announces Annual dividend, payable on July 21, 2025 M1 Kliniken AG announced Annual dividend of EUR 0.5000 per share payable on July 21, 2025, ex-date on July 17, 2025 and record date on July 18, 2025. Price Target Changed • Apr 25
Price target decreased by 7.7% to €25.83 Down from €28.00, the current price target is an average from 3 analysts. New target price is 61% above last closing price of €16.04. Stock is up 21% over the past year. The company is forecast to post earnings per share of €0.84 for next year compared to €0.54 last year. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €16.20, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 13x in the Healthcare industry in Germany. Total returns to shareholders of 119% over the past three years. New Risk • Mar 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. New Risk • Sep 16
New major risk - Revenue size The company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.4% average weekly change). Valuation Update With 7 Day Price Move • Sep 05
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to €16.55, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 14x in the Healthcare industry in Germany. Total returns to shareholders of 117% over the past three years. Upcoming Dividend • Jul 11
Upcoming dividend of €0.50 per share Eligible shareholders must have bought the stock before 18 July 2024. Payment date: 22 July 2024. Payout ratio is on the higher end at 93%, however this is supported by cash flows. Trailing yield: 3.0%. Lower than top quartile of German dividend payers (4.7%). In line with average of industry peers (3.2%). Buy Or Sell Opportunity • Jul 08
Now 21% undervalued Over the last 90 days, the stock has risen 24% to €17.05. The fair value is estimated to be €21.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.7% over the last 3 years. Earnings per share has declined by 6.0%. For the next 3 years, revenue is forecast to grow by 7.9% per annum. Earnings are also forecast to grow by 24% per annum over the same time period. Announcement • Jun 13
M1 Kliniken AG, Annual General Meeting, Jul 17, 2024 M1 Kliniken AG, Annual General Meeting, Jul 17, 2024, at 11:00 W. Europe Standard Time. Major Estimate Revision • Jun 09
Consensus EPS estimates increase by 21% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from €0.575 to €0.695. Revenue forecast steady at €341.4m. Net income forecast to grow 31% next year vs 16% growth forecast for Healthcare industry in Germany. Consensus price target up from €17.50 to €27.50. Share price was steady at €21.00 over the past week. Reported Earnings • May 28
Full year 2023 earnings released: EPS: €0.54 (vs €0.24 in FY 2022) Full year 2023 results: EPS: €0.54 (up from €0.24 in FY 2022). Revenue: €318.0m (up 12% from FY 2022). Net income: €10.3m (up 138% from FY 2022). Profit margin: 3.2% (up from 1.5% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • May 20
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €18.55, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 17x in the Healthcare industry in Germany. Total returns to shareholders of 86% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €37.02 per share. Valuation Update With 7 Day Price Move • May 02
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to €15.30, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 13x in the Healthcare industry in Germany. Total returns to shareholders of 51% over the past three years. New Risk • Mar 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.2% average weekly change). Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €14.25, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 13x in the Healthcare industry in Germany. Total returns to shareholders of 49% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €23.97 per share. New Risk • Feb 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Price Target Changed • Feb 20
Price target increased by 14% to €14.35 Up from €12.60, the current price target is an average from 2 analysts. New target price is 13% above last closing price of €12.65. Stock is up 77% over the past year. The company is forecast to post earnings per share of €0.40 for next year compared to €0.24 last year. Major Estimate Revision • Nov 23
Consensus EPS estimates increase by 16% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from €297.3m to €306.4m. EPS estimate increased from €0.31 to €0.36 per share. Net income forecast to grow 24% next year vs 24% growth forecast for Healthcare industry in Germany. Consensus price target up from €11.85 to €12.20. Share price rose 2.3% to €9.04 over the past week. Price Target Changed • Nov 22
Price target increased by 9.4% to €12.20 Up from €11.15, the current price target is an average from 2 analysts. New target price is 36% above last closing price of €9.00. Stock is up 89% over the past year. The company is forecast to post earnings per share of €0.36 for next year compared to €0.24 last year. Buying Opportunity • Nov 17
Now 20% undervalued Over the last 90 days, the stock is up 20%. The fair value is estimated to be €11.18, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has declined by 11%. Revenue is forecast to grow by 7.6% in 2 years. Earnings is forecast to grow by 35% in the next 2 years. Buying Opportunity • Oct 03
Now 21% undervalued Over the last 90 days, the stock is up 11%. The fair value is estimated to be €11.23, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has declined by 11%. Revenue is forecast to grow by 7.6% in 2 years. Earnings is forecast to grow by 35% in the next 2 years. Price Target Changed • Sep 28
Price target increased by 10% to €11.85 Up from €10.75, the current price target is an average from 2 analysts. New target price is 27% above last closing price of €9.36. Stock is up 143% over the past year. The company is forecast to post earnings per share of €0.31 for next year compared to €0.24 last year. Reported Earnings • Sep 14
First half 2023 earnings released: EPS: €0.17 (vs €0.07 in 1H 2022) First half 2023 results: EPS: €0.17 (up from €0.07 in 1H 2022). Revenue: €150.8m (up 8.7% from 1H 2022). Net income: €3.42m (up 148% from 1H 2022). Profit margin: 2.3% (up from 1.0% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Major Estimate Revision • Sep 03
Consensus EPS estimates increase by 13% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from €0.26 to €0.295. Revenue forecast steady at €296.8m. Net income forecast to grow 34% next year vs 29% growth forecast for Healthcare industry in Germany. Consensus price target up from €10.75 to €11.15. Share price rose 13% to €8.44 over the past week. Buying Opportunity • Aug 07
Now 20% undervalued Over the last 90 days, the stock is up 2.1%. The fair value is estimated to be €9.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has declined by 10%. For the next 3 years, revenue is forecast to grow by 6.1% per annum. Earnings is also forecast to grow by 27% per annum over the same time period. Buying Opportunity • Jul 13
Now 20% undervalued Over the last 90 days, the stock is up 11%. The fair value is estimated to be €9.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has declined by 10%. For the next 3 years, revenue is forecast to grow by 6.1% per annum. Earnings is also forecast to grow by 27% per annum over the same time period. Major Estimate Revision • Jun 27
Consensus EPS estimates fall by 10%, revenue upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €291.0m to €297.0m. EPS estimate fell from €0.29 to €0.26 per share. Net income forecast to grow 18% next year vs 15% growth forecast for Healthcare industry in Germany. Consensus price target of €10.75 unchanged from last update. Share price was steady at €7.58 over the past week. Buying Opportunity • Jun 20
Now 21% undervalued Over the last 90 days, the stock is up 20%. The fair value is estimated to be €9.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has declined by 10%. For the next 3 years, revenue is forecast to grow by 7.1% per annum. Earnings is also forecast to grow by 29% per annum over the same time period. New Risk • Jun 15
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.5% Last year net profit margin: 2.8% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company. Reported Earnings • Jun 14
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: EPS: €0.22 (down from €0.48 in FY 2021). Revenue: €286.8m (down 8.8% from FY 2021). Net income: €4.32m (down 52% from FY 2021). Profit margin: 1.5% (down from 2.8% in FY 2021). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.3%. Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 9% per year whereas the company’s share price has fallen by 8% per year. Major Estimate Revision • Jun 02
Consensus EPS estimates fall by 11% The consensus outlook for fiscal year 2022 has been updated. 2022 EPS estimate fell from €0.27 to €0.24 per share. Revenue forecast steady at €285.3m. Net income forecast to shrink 25% next year vs 5.2% growth forecast for Healthcare industry in Germany . Consensus price target up from €10.50 to €10.75. Share price rose 5.8% to €8.46 over the past week. Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €8.10, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 24x in the Healthcare industry in Germany. Total loss to shareholders of 24% over the past three years. Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to €7.08, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 20x in the Healthcare industry in Germany. Total loss to shareholders of 20% over the past three years. Valuation Update With 7 Day Price Move • Jan 16
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €7.42, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 15x in the Healthcare industry in Germany. Total loss to shareholders of 50% over the past three years. Valuation Update With 7 Day Price Move • Dec 15
Investor sentiment improved over the past week After last week's 17% share price gain to €7.06, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 15x in the Healthcare industry in Germany. Total loss to shareholders of 45% over the past three years. Valuation Update With 7 Day Price Move • Nov 29
Investor sentiment improved over the past week After last week's 16% share price gain to €5.50, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 16x in the Healthcare industry in Germany. Total loss to shareholders of 59% over the past three years. Price Target Changed • Nov 16
Price target decreased to €10.85 Down from €12.00, the current price target is an average from 2 analysts. New target price is 130% above last closing price of €4.72. Stock is down 39% over the past year. The company is forecast to post earnings per share of €0.28 for next year compared to €0.48 last year. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €5.32, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 15x in the Healthcare industry in Germany. Total loss to shareholders of 61% over the past three years. Major Estimate Revision • May 27
Consensus revenue estimates fall by 19% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from €358.4m to €290.4m. EPS estimate fell from €0.44 to €0.33 per share. Net income forecast to shrink 26% next year vs 6.7% growth forecast for Healthcare industry in Germany . Consensus price target down from €14.00 to €13.00. Share price fell 6.3% to €6.26 over the past week. Announcement • May 23
M1 Kliniken AG, Annual General Meeting, Jul 13, 2022 M1 Kliniken AG, Annual General Meeting, Jul 13, 2022. Reported Earnings • May 22
Full year 2021 earnings: Revenues miss analyst expectations Full year 2021 results: Net income: €8.91m (up 31% from FY 2020). Revenue missed analyst estimates by 4.5%. Price Target Changed • Apr 27
Price target decreased to €14.00 Down from €20.00, the current price target is an average from 2 analysts. New target price is 95% above last closing price of €7.18. Stock is down 35% over the past year. The company is forecast to post earnings per share of €0.43 for next year compared to €0.37 last year. Announcement • Apr 02
M1 Kliniken AG to Report Fiscal Year 2021 Final Results on May 19, 2022 M1 Kliniken AG announced that they will report fiscal year 2021 final results on May 19, 2022 Buying Opportunity • Feb 04
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 8.8%. The fair value is estimated to be €9.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 57% per annum over the last 3 years. Earnings per share has grown by 11% per annum over the last 3 years. Valuation Update With 7 Day Price Move • Aug 30
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €8.20, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 15x in the Healthcare industry in Germany. Total loss to shareholders of 51% over the past three years. Price Target Changed • Jul 07
Price target increased to €20.00 Up from €16.40, the current price target is an average from 3 analysts. New target price is 94% above last closing price of €10.30. Stock is down 5.5% over the past year. Valuation Update With 7 Day Price Move • Jun 04
Investor sentiment improved over the past week After last week's 16% share price gain to €11.80, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 24x in the Healthcare industry in Germany. Total loss to shareholders of 28% over the past three years. Reported Earnings • May 30
Full year 2020 earnings released: EPS €0.37 (vs €0.56 in FY 2019) The company reported a decent full year result with improved revenues, although earnings and profit margins were weaker. Full year 2020 results: Revenue: €159.6m (up 107% from FY 2019). Net income: €6.82m (down 30% from FY 2019). Profit margin: 4.3% (down from 13% in FY 2019). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Mar 08
New 90-day high: €9.54 The company is up 3.0% from its price of €9.24 on 08 December 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €66.16 per share. Price Target Changed • Jan 19
Price target lowered to €16.40 Down from €17.88, the current price target is an average from 4 analysts. The new target price is 86% above the current share price of €8.84. As of last close, the stock is down 40% over the past year. Announcement • Dec 01
M1 Kliniken AG Announces Resignation of Patrick Brenske from the Management Board M1 Kliniken AG announced that as of November 30, 2020 Mr. Patrick Brenske will join the Management Board of HAEMATO AG. At the same time, Mr. Brenske will resign from the Management Board of M1 Kliniken AG, with Dr. Walter von Horstig from now on acting as sole member of the Management Board. Mr. Brenske will continue to advise M1. Major Estimate Revision • Nov 27
Analysts update estimates The 2020 consensus revenue estimate increased from €171.8m to €179.5m. Earnings per share (EPS) estimate was lowered from €0.31 to €0.28 for the same period. Net income is expected to grow by 2.4% next year compared to 14% growth forecast for the Healthcare industry in Germany. The consensus price target was lowered from €18.08 to €17.88. Share price is up 2.4% to €9.52 over the past week. Valuation Update With 7 Day Price Move • Nov 11
Market bids up stock over the past week After last week's 15% share price gain to €9.58, the stock is trading at a trailing P/E ratio of 21.3x, up from the previous P/E ratio of 18.5x. This compares to an average P/E of 19x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 11%. Is New 90 Day High Low • Oct 29
New 90-day low: €7.96 The company is down 16% from its price of €9.50 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €16.94 per share.